Showing 2774 results
-
Press release /New ALITHIOS data show mean immunoglobulin G (IgG) levels in people treated with Kesimpta remained unchanged over 3.5 years and mean immunoglobulin M (IgM) levels remained within the reference range1…
-
Press release /Novartis is collaborating with Hewlett Packard Enterprise to accelerate the use of data and digital technologies within its efforts to reimagine global health and improve access to healthcare and…
-
Press release /VISION manuscript shows that 177Lu-PSMA-617 plus standard of care (SOC) significantly improved overall survival and radiographic progression-free survival for patients with metastatic castration-…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21…
-
Ad hoc release /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs im zweiten Quartal um +9% (kWk¹, +14% USD): Die Geschäftseinheit Pharmaceuticals legte +12% (kWk, +18% USD) zu mit…
-
Press release /New findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
-
Press release /Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
-
Press release /Acquisition underscores Novartis commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness Novartis gains one pre-clinical optogenetic AAV gene therapy…
-
Press release /Cette acquisition souligne l’engagement de Novartis à utiliser des thérapies basées sur l’optogénétique pour redonner la vue aux patients atteints de cécité avancéeNovartis acquiert un programme…